GlaxoSmithKline set to exit Nigeria after 51 years of operation
GlaxoSmithKline (GSK), a British pharmaceutical and biotechnology company, has announced its plan to exit Nigeria after 51 years of operation in Nigeria.
However, GSK Nigeria, in a statement by its secretary, Fredrick Ichekwai, said the exit would be in the coming months. The statement was sent to the Nigeria Exchange Limited (NGX).
The company said it resolved to exit the West African country after its board meeting and evaluation of options with GSK UK.
“The board of GlaxoSmithKline Consumer Nigeria Plc has concluded that there is no alternative but to cease operations,” GSK Nigeria said.
The development comes two months after the company lamented the difficulty in accessing currency, stating that it affected its supply of products to Nigeria.
“The challenge in accessing currency is affecting our ability to maintain a consistent supply of medicines and vaccines in the market,” it said in a statement by its spokesperson, Omongiade Ehighebolo.
Nonetheless, the company, in its latest statement, said it would appoint third-party distributors to supply medicines and healthcare products in Nigeria.
“The Haleon Group has also separately informed the board of its intent to terminate its distribution agreement in the coming months and to appoint a third-party distributor in Nigeria for the supply of its consumer healthcare products,” it said.
GSK Nigeria said it would ensure it meets legal requirements on the development with its employees and shareholders.
It advised shareholders to seek professional advice and exercise caution when dealing with the company’s shares until a further announcement.
“The Board is conscious that shareholders will have many questions; we have been working assiduously with our professional advisors to agree on the next steps, and we will be shortly submitting to the Securities and Exchange Commission (“SEC”) a draft Scheme of Arrangement which may if approved, see shareholders other than GSK UK, receive an accelerated cash distribution and return of capital,” it said.
GlaxoSmithKline Consumer Nigeria Plc was incorporated in Nigeria on June 23, 1971, and commenced business on July 1, 1972, under Beecham Limited.
The company was quoted on the Nigerian Stock Exchange in 1977.
We have recently deactivated our website's comment provider in favour of other channels of distribution and commentary. We encourage you to join the conversation on our stories via our Facebook, Twitter and other social media pages.
More from Peoples Gazette
Politics
Katsina youths pledge to deliver over 2 million votes to Atiku
“Katsina State is Atiku’s political base because it is his second home.”
Lagos
Igando Hospital scales down services over death of doctor
Places like the eye unit, dental department, laboratory, pharmacy hospital and others, always filled with patients, were deserted.
States
Police neutralise three kidnappers, arrest cattle rustlers in Bauchi
He noted that the command’s unrelenting and aggressive counter-kidnapping strategies had led to successful fights against kidnapping
States
Kaduna tribunal fixes August 5 for Gov. Sani to defend his victory
It ordered that the respondents open and close their defence within the 10 days stipulated by the law.
Kano
Kano anti-graft agency arrests father, son over missing N4 billion govt. fund
It stated that the suspect was arrested after breaking into sealed warehouses confiscated by the PCACC.
Enugu
Assembly screens, clears 15 commissioner-nominees in Enugu
Speaker of the house, Uchenna Ugwu (PDP-Udi North), allowed members to quiz the commissioner-nominees.
Health
Diphtheria killed 122 Nigerian children in seven months: UNICEF
Ms Akau stated that 3,850 suspected cases of diphtheria were reported as of July and that 1,387 were confirmed.
